⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
prnewswire.com
BIIB
サムスンエピスホールディングス、2025年度第4四半期および通期決算を発表
businesswire.com
AMGN
REGN
JNJ
BIIB
Samsung Epis Holdings公布2025年第四季度及财年财务业绩
businesswire.com
AMGN
REGN
JNJ
BIIB
Samsung Epis Holdings meldet Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2025
businesswire.com
AMGN
BIIB
GEN
JNJ
REGN
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results
businesswire.com
AMGN
JNJ
REGN
BIIB
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA USA - English USA - English
prnewswire.com
BIIB
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA USA - English USA - English
prnewswire.com
BMY
BIIB
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
prnewswire.com
BIIB
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
globenewswire.com
BIIB
CD137 Targeted Therapy Research Report 2026-2030: 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global & Regional Clinical & Commercial Trends,
globenewswire.com
GILD
BMY
REGN
MRK
GENM
ABL
BNTX
BIIB